Effectiveness of Homoharringtonine (Omacetaxine Mepesuccinate) for Treatment of Acute Myeloid Leukemia: A Meta-Analysis of Chinese Studies
作者： Hagop Kantarjian , Susan O'Brien , Elias Jabbour , Gisoo Barnes , Ashutosh Pathak
DOI: 10.1016/J.CLML.2014.09.011
关键词:
摘要: The present meta-analysis provides an overview on the effectiveness of homoharringtonine (HHT) combination regimens to treat acute myeloid leukemia (AML). Because most these studies were performed in China, Chinese published clinical used for analysis. A search from 2006 2013 containing HHT AML treatment was using and databases Mandarin. complete response (CR) overall (OR) rates analyzed, fixed effects model random (REM) calculated. heterogeneity calculated Q homogeneity statistics. included 21 (n = 1310, n 229 pediatric, 216 elderly). given with cytarabine, daunorubicin, idarubicin, aclacinomycin, mitoxantrone, or granulocyte colony-stimulating factor. Heterogeneity seen all analyzed pools, but it pronounced retrospective studies. Overall, REM showed a CR rate 65.2%. However, which HHT-containing compared without HHT, 69.1% randomized trials 62.8% Additionally, exclusively elderly patients, considerably lower than mixed age populations (47.5% vs. 65.2%). Higher suggest that could be active agent management AML. Additional are warranted evaluate efficacy treatment.
clinical-lymphoma-myeloma-leukemia.com
elsevier.com
sci-hub.se 参考文章(28)
Anne Whitehead, Meta-Analysis Of Controlled Clinical Trials Statistics in Practice. ,(2002) , 10.1002/0470854200
Hong-Yan Tong, Wen-Yuan Mai, Hai-Tao Meng, Jie Jin, Yin Tong, Wen-Bin Qian, Jian Huang, Dao-Zi Jiang, Lei Wang, Li-Ping Mao, Hui Liu, HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia Chinese Journal of Hematology. ,vol. 29, pp. 9- 12 ,(2008)
S. S. Legha, M. Keating, S. Picket, Michael S Ewer, G. P. Bodey, J. A. Ajani, Phase I clinical investigation of homoharringtonine. Cancer treatment reports. ,vol. 68, pp. 1085- 1091 ,(1984)
Wan-mao Ni, Jian-ping Shen, Wen-bin Qian, Hong Yang, [Cytotoxicity of homoharringtonine on leukemic stem-like cells in AML cell line KG-1]. Journal of Zhejiang University (Medical Sciences). ,vol. 41, pp. 485- 490 ,(2012)
Rebecca DerSimonian, Raghu Kacker, Random-effects model for meta-analysis of clinical trials: An update Contemporary Clinical Trials. ,vol. 28, pp. 105- 114 ,(2007) , 10.1016/J.CCT.2006.04.004
J Jin, D-Z Jiang, W-Y Mai, H-T Meng, W-B Qian, H-Y Tong, J Huang, L-P Mao, Y Tong, L Wang, Z-M Chen, W-L Xu, Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia. ,vol. 20, pp. 1361- 1367 ,(2006) , 10.1038/SJ.LEU.2404287
Bin-Tao Huang, Qing-Chun Zeng, Jessica Yu, Xiao-Li Liu, Zhen Xiao, Hong-Qian Zhu, High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China Medical Oncology. ,vol. 29, pp. 251- 259 ,(2012) , 10.1007/S12032-011-9820-4
Liu-Fang Gu, Wang-Gang Zhang, Fang-Xia Wang, Xing-Mei Cao, Yin-Xia Chen, Ai-Li He, Jie Liu, Xiao-Rong Ma, Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia Journal of Cancer Research and Clinical Oncology. ,vol. 137, pp. 997- 1003 ,(2011) , 10.1007/S00432-010-0947-Z
Hagop M. Kantarjian, Moshe Talpaz, Valeria Santini, Anthony Murgo, Bruce Cheson, Susan M. O'Brien, Homoharringtonine: History, current research, and future directions Cancer. ,vol. 92, pp. 1591- 1605 ,(2001) , 10.1002/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U
Theo Daniel Kim, Mareike Frick, Philipp le Coutre, Omacetaxine mepesuccinate for the treatment of leukemia. Expert Opinion on Pharmacotherapy. ,vol. 12, pp. 2381- 2392 ,(2011) , 10.1517/14656566.2011.613378